F-Prime backs a niche AI software startup hunting lofty goals in $22M Series B
For many of the AI companies sprouting on the biopharma field, validation — often meaning confirmation of whether the targets and drugs they identified or generated would actually work — won’t come in years, if at all. But for BenchSci, the drug hunting field is their home turf.
To be sure, the Toronto-based startup is doing something very different from the rest of the pack. Rather than staking claims about the results of drug discovery, it’s out to change the process by hunkering down on a specific problem: helping scientists select the right reagents to conduct their preclinical experiments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
